CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Agenus Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Agenus Inc
3 Forbes Rd
Phone: (302) 658-7581p:302 658-7581 LEXINGTON, MA  02421-7305  United States Ticker: AGENAGEN
Business Summary
Agenus Inc. is a clinical-stage biotechnology company focused on discovering and developing immunotherapies for cancer and infectious disease. The Company's primary business is immuno-oncology, which is advancing antibody-based programs to activate innate and adaptive immunity, overcome tumor immune evasion and expand the population of patients from immunotherapy. Its lead clinical program is botensilimab, alone and in combination with balstilimab, is a clinical-stage immuno-oncology asset which may be used as standalone agents or be complimentary to botensilimab plus balstilimab. Its internal discovery and translation platforms support target identification, antibody generation, biomarker analysis, and candidate selection. The Company's clinical and preclinical portfolio include agents directed to CTLA-4, PD-1, CD137, CD73/TGF-beta, ILT2, LAG-3, TIM-3, and TIGIT, all of which remain as proprietary assets of Agenus.
(Source: 6-K)

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
6/30/202612/31/2025YesYes--Yes

Industries
SIC Code Description
8731 Commercial physical and biological research
2836 Biological products, except diagnostic substances

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chairman of the Board, Chief Executive Officer, Co-Founder, Principal Financial Officer Garo H.Armen 73 1/8/2026 1/1/1994
Chief Medical Officer StevenO'Day 65 1/1/2021 1/1/2021
Lead Independent Director Thomas L.Harrison 78 7/1/2025 8/7/2024
4 additional Officers and Directors records available in full report.

Subsidiaries
Business Name Address City State/Province Country
AGENUS UK 315 MILTON ROAD CAMBRIDGE
AGENTUS THERAPEUTICS LTD MILTON ROAD CAMBRIDGE
4-Antibody AG Schwarzwaldallee 215 CH-4002 Basel Switzerland
3 additional Subsidiary records available in full report.

Business Names
Business Name
4-Antibody AG
AGEN
AgenTus Therapeutics Limited
9 additional Business Names available in full report.

General Information
Number of Employees: 81 (As of 2/28/2026)
Outstanding Shares: 45,020,407 (As of 8/4/2026)
Shareholders: 178
Stock Exchange: NASD
Federal Tax Id: 061562417
Fax Number: (302) 655-5049
Email Address: ir@antigenics.com


Copyright © 2026 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Friday, September 11, 2026